+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy



Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy



Pediatric Radiology 32(6): 405-408



Seven infants with ductal dependent cyanotic congenital heart disease are reported. All were on prostaglandin E1 therapy to maintain ductus patency. All showed chest radiographic evidence of multiple masses indenting the stomach lumen (gastric thumbprinting). Other than feeding intolerance in two patients, the findings were incidental and disappeared with cessation of PGE1 therapy. "Gastric thumbprinting" appears to be a more common consequence of PGE1 therapy than actual obstructing antral masses (antral foveolar hyperplasia).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046149390

Download citation: RISBibTeXText

PMID: 12029339

DOI: 10.1007/s00247-002-0690-y


Related references

Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. Journal of Pediatrics 97(5): 834-836, 1980

Reversibility of cortical hyperostosis following long-term prostaglandin E1 therapy in infants with ductus-dependent congenital heart disease. Pediatric Radiology 18(2): 149-153, 1988

Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease. Journal of Thoracic and Cardiovascular Surgery 90(3): 399-403, 1985

Complications of Long-Term Prostaglandin E1 Use in Newborns With Ductal-Dependent Critical Congenital Heart Disease. Journal of Perinatal and Neonatal Nursing 30(1): 73-79, 2017

Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease. European Journal of Pediatrics 146(3): 279-282, 1987

Isolated IgG4-related gastric disease presenting as diffuse gastric wall thickening with ulcer. Journal of Radiology Case Reports 12(9): 9, 2018

Long term use of oral prostaglandin in cyanotic congenital heart disease. Pediatric Research 39(4 Part 2): 34A, 1996

Increase in pulmonary arterial diameter under prostaglandin E1 therapy in infants with cyanotic congenital heart disease. Pediatric Cardiology 19(5): 404-407, 1998

Prostaglandin treatment of infants with cyanotic congenital heart disease. The Journal of Pediatrics 96(1): 158, 1980

Prostaglandin E1 therapy in infants with cyanotic congenital heart malformations: hemodynamic and angiographic findings. Klinische Padiatrie 190(5): 465-473, 1978

Prostaglandin E1: effect on blood gases in infants with cyanotic congenital heart disease. Klinische Padiatrie 189(5): 365-369, 1977

Transcutaneous PO2 monitoring in infants with cyanotic congenital heart disease treated with prostaglandin E1. Pediatric Cardiology 4(2): 87-89, 1983

Early postoperative physical therapy for improving short-term gross motor outcome in infants with cyanotic and acyanotic congenital heart disease. Disability and Rehabilitation 40(14): 1694-1701, 2018

Effects of prostaglandin e 1 on polymorphonuclear leukocyte function in infants with cyanotic congenital heart disease. Pediatric Research 16(4 Part 2): 219A, 1982

Gross thickening of the rat gastric mucosa after long term administration of 16 16 di methyl prostaglandin e 2. Gastroenterology 82(5 Part 2): 1159, 1982